Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortosiran versus apixaban in non-valvular atrial fibrillation
2026-525417-31-00Phase 2Authorised
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Oct 2026
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of vortosiran and apixaban in nonvalvular atrial fibrillation (NVAF) (3 arms), sponsored by Ribocure Pharmaceuticals AB. Primary endpoint: Percentage change in factor XI activity from baseline at Week 16. Planned start Oct 2026; status: authorised.
02
Drugs
vortosiranapixaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on 2026-525417-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525417-31-00.